Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat and Ipilimumab in Metastatic AVPC, UC, and RCC
NCT04388852Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of valemetostat in prostate carcinoma, urothelial carcinoma (UC) and renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events and Maximum tolerated dose up to 21 days. Started Aug 2020; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
prostate carcinomaurothelial carcinoma (UC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04388852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388852.